Check valve

Information

  • Patent Grant
  • 11364372
  • Patent Number
    11,364,372
  • Date Filed
    Friday, June 21, 2019
    4 years ago
  • Date Issued
    Tuesday, June 21, 2022
    a year ago
Abstract
A check valve for use in a fluid pathway. The check valve may have a diaphragm and a plurality of supports extending from the diaphragm. The check valve and supports have a line of symmetry, and deformation of the check valve as it moves from a closed position to an opened position can be generally along the line of symmetry.
Description
BACKGROUND
Field of the Disclosure

A variety of devices and techniques exist for the manipulation of fluids in hospitals and medical settings, and in particular the selective facilitation of fluid movement to or from patients or to or from a fluid flow line. Fluid flow lines rely on a variety of connectors to help develop preferred flow characteristics or access points. Many connectors include check valves.


Description of the Related Art

Current fluid flow systems, medical connectors, and check valves have various limitations and disadvantages and a need exists for further improvement.


SUMMARY OF THE DISCLOSURE

A variety of fluid flow lines and systems are used in hospitals and medical settings for the selective facilitation of fluid movement to or from patients. For example, central venous catheters can be used to administer IV fluids, various medications or blood products, and/or parenteral nutrition. In some embodiments, medical connectors can be provided on one end of a flow line to allow for periodic access to a flow line or for application of different inputs to the flow line. Generally, these structures require valves to allow fluid to enter the main flow line while preventing retrograde flow.


In certain situations, it may be desirable to provide multiple connections to a flow line into a patient's blood stream. This can allow for easy connection to multiple fluid or medication sources. This is particularly useful in treatments that require multiple inputs, such as chemotherapy. When multiple connections are desired, a manifold, extension set, or other multi-input structure can be used. These structures also require valves to allow fluid to enter the main flow line but that preferably prevent retrograde flow. In various embodiments described herein, such valves can be designed to maximize efficiency and desired flow rates and flow characteristics while still providing a check on retrograde flow. In some situations, it may be desirable to provide a single connection point with one way flow.


In various embodiments, a medical check valve for use in a medical device to provide one-way fluid flow between a first fluid location and a second fluid location can include a flexible diaphragm having a top surface, a bottom surface, and a side wall between the top surface and the bottom surface, and a first support member extending from the bottom surface of the flexible diaphragm and a second support member extending from the bottom surface of the flexible diaphragm, the first support member and second support member positioned to define a line of or axis of symmetry that bisects the bottom surface without passing through the first support member or the second support member. The flexible diaphragm can have a first position in which the top surface is generally planar and is configured to seal against a fluid opening and a second position in which the top surface of the diaphragm is curved generally around the line of symmetry and is configured to be displaced from the fluid opening.


In some embodiments, the line of symmetry can be the only line of symmetry that bisects the bottom surface without passing through the first support member or the second support member. In some embodiments, the flexible diaphragm can be a disc. In some embodiments, the support members can be positioned 180 degrees apart about the disc. In some embodiments, the flexible diaphragm can be nonperforate. In some embodiments, the flexible diaphragm, the first support member, and the second support member can be integrally formed and/or molded into a single unitary piece.


In some embodiments, the diaphragm can be configured to move from the first position to the second position at varying amounts of pressure. For example, in some embodiments a net pressure of less than 3 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position. In some embodiments, a net pressure of less than 1 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position. In some embodiments, a positive net pressure on the bottom surface of the flexible diaphragm is needed to maintain the flexible diaphragm in the first position.


In various embodiments, a medical manifold for use in providing access to a fluid flow path can include a housing having a first port, a second port, a first channel connecting the first port and the second port and defining a first flow path, and a third port having a recess in an outer wall of the housing and a second channel fluidly connecting the recess and the first flow path. The manifold can also include a valve member having a diaphragm and a plurality of support members configured to be positioned in the recess to thereby define a space between a bottom wall of the recess and the diaphragm. The manifold can also include a medical connector configured to attach to the third port, wherein the valve member in a closed position is configured to seal against an opening into the medical connector and the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member, through the second channel, and into the first flow path.


In some embodiments, an outer wall of the recess can be cylindrical. In some embodiments, an outer wall of the recess can include multiple walls. In some embodiments, the third port can have at least two projections extending from the bottom wall of the recess and adjacent the second channel, wherein the projections define an outer channel between the projections and an outer wall of the recess and at least two transverse channels between the projections. In some embodiments, the plurality of support members can be configured to be positioned on at least two of the projections. In such embodiments, the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member to the outer channel, through the transverse channels, and into the second channel.


In some embodiments, the valve member can be biased toward the closed position. In some embodiments, the valve member can be configured to move from the closed to the open position as a result of pressure from fluid in the medical connector. In some embodiments, the housing can be monolithic. In some embodiments, a net pressure of less than 3 psi on the valve member can be sufficient to move the valve member from the closed position to the open position.


In various embodiments, a medical manifold for use in providing access to a fluid flow path can include a first port, a second port, a first channel connecting the first port and the second port and defining a first flow path, and a housing having a third port in an outer wall of the housing and a second channel fluidly connecting the third port and the first flow path. The manifold can also include a valve member having a diaphragm and a plurality of support members configured to be positioned in the third port to thereby define a space between a bottom wall of the third port and the diaphragm. The manifold can also include a medical connector configured to attach to the third port, wherein the valve member in a closed position is configured to seal against an opening into the medical connector and the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member, through the second channel, and into the first flow path.


In some embodiments, the third port further includes at least two projections extending from the bottom wall of the third port and adjacent the second channel, wherein the projections define at least two transverse channels between the projections. The plurality of support members may be configured to be positioned on at least two of the projections. In some embodiments, the third port of the medical manifold includes a recess and the projections extend from the bottom wall of the recess. A wall surrounding the recess may extend outward from the housing and a portion of the medical connector may be configured to surround at least a portion of the wall. In some embodiments, the medical connector is sonically welded to the third port.


In some embodiments, an outer wall of the third port can be cylindrical. In some embodiments, an outer wall of the third port can include multiple walls. In some embodiments, the third port can have at least two projections extending from the bottom wall of the third port and adjacent the second channel, wherein the projections define an outer channel between the projections and an outer wall of the third port and at least two transverse channels between the projections. In some embodiments, the plurality of support members can be configured to be positioned on at least two of the projections. In such embodiments, the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member to the outer channel, through the transverse channels, and into the second channel.


In various embodiments, a medical manifold for use in providing access to a fluid flow path can include a first port, a second port, a first channel connecting the first port and the second port and defining a first flow path, and a housing having a third port in an outer wall of the housing and a second channel fluidly connecting the third port and the first flow path. The manifold can also include a valve member having a diaphragm and a plurality of support members configured to be positioned in the third port to thereby define a space between a bottom wall of the third port and the diaphragm. The manifold can also include a medical connector configured to attach to the third port, wherein the valve member in a closed position is configured to seal against an opening into the medical connector and the valve member in an open position is configured to allow fluid to flow from the medical connector, past the valve member, through the second channel, and into the first flow path. The medical manifold can also include a second housing including a fourth port with a third channel fluidly connecting the fourth port and the first flow path. In some embodiments, the manifold can include a second valve member with a diaphragm and a plurality of support members configured to be positioned in the fourth port to thereby define a space between a bottom wall of the fourth port and the diaphragm. Some manifolds can include a second medical connector configured to attach to the fourth port, wherein the second valve member in a closed position is configured to seal against an opening into the second medical connector and the second valve member in an open position is configured to allow fluid to flow from the second medical connector, past the second valve member, through the third channel, and into the first flow path. In some embodiments, the first and second housings are monolithic while in other embodiments, wherein the first and second housings are joined by a flexible connecting element.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of one embodiment of a manifold.



FIG. 1A is a perspective view of an embodiment of a manifold with a modified projection attachment.



FIG. 1B is a perspective view of an embodiment of a manifold component.



FIG. 2 is a perspective view of one embodiment of a manifold.



FIG. 2A is a perspective view of an embodiment of a manifold with a modified projection attachment.



FIG. 2B is a perspective view of an embodiment of a manifold component.



FIG. 3 is a cross-sectional view of the manifold of FIG. 1.



FIG. 3A is a cross-sectional view of the manifold of FIG. 1A.



FIG. 3B is a cross-sectional view of the manifold of FIG. 1B.



FIG. 4 is a cross-sectional view of the manifold of FIG. 2.



FIG. 4A is a cross-sectional view of the manifold of FIG. 2A.



FIG. 4B is a cross-sectional view of the manifold of FIG. 2B.



FIG. 5 is a perspective view of one embodiment of a port of a manifold.



FIG. 5A is a perspective view of an embodiment of a port of a manifold.



FIG. 6 is a top view of the port of FIG. 5.



FIG. 7 is a bottom perspective view of one embodiment of a check valve.



FIG. 8 is a top perspective view of the check valve of FIG. 7.



FIG. 9 is a bottom view of the check valve of FIG. 8.



FIG. 10 is a side view of the check valve of FIG. 9.



FIG. 11A is a cross-sectional view of one embodiment of a port of a manifold with a check valve.



FIG. 11B is a cross-sectional view of one embodiment of a port of a manifold with an attached medical connector, with a check valve not shown.



FIG. 12A is a cross-sectional view of one embodiment of a port of a manifold with an attached medical connector and a check valve in a closed position.



FIG. 12B is a cross-sectional view of the embodiment of FIG. 12A with the check valve in an open position.



FIG. 13A is a cross-sectional view of one embodiment of a port of a manifold with an attached medical connector and a check valve in a closed position.



FIG. 13B is a cross-sectional view of the embodiment of FIG. 13A with the check valve in an open position.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

With reference to the attached figures, certain embodiments and examples of fluid flow systems, medical connectors, and valves will now be described. Various embodiments of check valves described herein are with reference to a manifold or extension set, but they are not so limited. In some aspects, they can be applied to any system to provide for one-way flow between a medical connector and a fluid flow line, such as in, for example, IV sets, stopcocks or other branched connectors including y-site connectors, and other systems. As used herein, the term “fluid” refers to either gases or liquids.



FIG. 1 illustrates an embodiment of a manifold 10 that can be used to provide access to a fluid flow path. The manifold can include a manifold housing 12 that can include a first port 20 and a second port 30. In some embodiments, the housing can be one integral piece, and in some embodiments it can include multiple pieces such that the manifold includes first and second ports connected by a fluid path, but the ports are connected by separately formed units, for example tubes, to the housing. In some embodiments, multiple housings may be connected between the first and second ports. Preferably, even when connected by flexible joints, the manifold in a resting position defines a generally linear fluid path between the first and second ports with one or more ports branching off that path. In some embodiments, those one or more ports branch off at about 90 degrees from the flow path between the first and second ports. The manifold can be inserted into a fluid flow line with the first port 20 configured to attach to one end of the line and the second port 30 configured to attach to a second end of the line. The ports can be configured to accommodate any standard medical connector or implement, and can be adapted to conform with ANSI (American National Standards Institute) or other applicable standards. In some embodiments, different ports can also be configured to have nonstandard connections.


In some embodiments, a first port 20 can have a threaded end 22 that can be used to connect to a threaded medical connector. In some embodiments, a second port 30 can have a male luer lock 32, including a tapered cannula 34 (visible in FIGS. 3 and 4).


In some embodiments, the manifold 10 can include a plurality of access ports 40, described and illustrated in more detail below. The access ports can be adapted to connect or attach to a variety of types of medical connectors 50. In some embodiments, as illustrated, a medical connector 50 can be a needleless connector. In the illustrated embodiment, the manifold includes six medical connectors 50, three on a first side of the manifold and three on a second side of the manifold.


In various embodiments, a manifold can have varying numbers of access ports and medical connectors. For example, FIG. 2 illustrates an embodiment of a manifold 10′″ that has three access ports and medical connectors 50 on one side of the manifold. Housing 12′″ includes joints 16′″ and can include an extended portion or fin 13 that may be positioned on the side opposite the medical connectors. Fin 13′″ can be provided to add stability to the manifold 10′″ and may be configured to facilitate the handling or control by a nurse or other user of the manifold 10′″ during use or to attach the manifold 10′ to a convenient resting place. FIG. 2A shows an alternative manifold 10″″ also including three access ports and medical connectors 50′ on one side. Housing 12″″ includes joints 16″″ and can include an extended portion or fin 13″″ that may be positioned on the side opposite the medical connectors. Fin 13″″ can be provided to add stability to the manifold 10″″ and may be configured to facilitate the handling or control by a nurse or other user of the manifold 10″″ during use or to attach the manifold 10″″ to a convenient resting place. As shown, joints 16′″ may include shallow curved portions as compared to the curved portions on joints 16′″ shown in FIG. 2. Curved portions and other structures can be used to change the strength of the housing and to provide a convenient place to hold the manifold.


Other combinations of ports are also possible. For example, FIG. 1B shows a manifold 10″ including two double housings 12″. FIG. 2B shows a manifold 10′″″ including two single housings 12′″″. As discussed above, a single manifold may include various combinations of such housings as desired.


Embodiments of the invention may provide various ways to connect medical connectors to the housing ports, as discussed in greater detail below. For example, FIG. 1A shows a six port manifold 10′ with alternative ports 40′ and modified connectors 50′.


As shown, in some embodiments various modifications can be made to the connecting portions or joints 16 between the ports. For example, FIG. 1 shows a first version of the joints 16 while FIG. 1A shows an alternative joint 16′ that includes shallow arched or curved portions. As shown in FIG. 1B, in some embodiments, rather than having a single housing 12 (see, for example, FIGS. 1 and 1A), a manifold 10″ can have a plurality of housings 12″ joined by a flexible connecting portion, for example, tubing. Thus, for example, in some embodiments the joints 16″ of the manifolds that connect housings having medical connectors or pairs of medical connectors can be formed of tubing.



FIG. 1B shows two double housings 12″. Various combinations are also possible. In some embodiments, a single housing 12″ with double ports may be provided and can be accessed by first and second ports 20′ and 30. First port 20′ may be similar to first port 20, except the rigid portion may be longer to accommodate the appropriate section of a medical implement, for example, a male luer. In some embodiments, the manifold may include 3 or more housings 12″ with corresponding medical connectors. Accordingly, the manifold can readily customized to provide an appropriate solution according to a user's needs. In addition, the manifold may include a combination of housings and ports, for example, a manifold may be provided with one or more double housing 12″ and one or more single housings 12′″″ (see FIG. 2B). Providing flexible joints allows the manifold to flex and adapt to the needs of the user. For example, a port may be rotated to ease access while minimizing the movement of other ports that may already be accessed by various medical devices. The flexible joints of the manifold are permanently attached, for example by bonding or glueing, to their respective housings and ports such that the manifold is a single unity.


In some embodiments, various ports may remain connected or unconnected to one or more fluid sources and/or to a patient. For example, in some embodiments, one of the first port 20 and second port 30 can be connected to a patient, the other of the first port and second port may be sealed (such as with a medical connector 50 or a similar sealed access port) and unconnected to a fluid source, and one or more of the medical connectors 50 can be connected to a fluid source for the patient. In some embodiments, embodiments of the manifold can be used without a patient, for example, to combine one or more fluids into a single fluid receptacle (not shown). Accordingly, embodiments of the invention need not be used in direct connection with a patient.



FIGS. 3 and 4 illustrate cross-sectional views of the manifolds of FIGS. 1 and 2, respectively. As illustrated, medical connectors 50 can attach to the manifold at access ports 40. In some embodiments, a medical connector 50 can be a needleless medical connector that includes a connector body 60, a connector base 70, and a connector valve member 80 positioned at least partially within the connector body 60. Further details regarding needless medical connectors that can be used are found in U.S. Provisional Patent Application No. 61/914,680, filed Dec. 11, 2013, the entire contents of which are hereby incorporated by reference herein and are included as an appendix to this application.


In some embodiments, other types of medical connectors or of needleless medical connectors can be attached to the access ports 40 of the manifolds. These can include connectors configured to receive syringes and connectors of varying designs. In some embodiments, a manifold can include one or more of a first type of medical connector and one or more of a second type of medical connector. In some embodiments, a manifold can include more than two types of medical connectors. In some embodiments, first port 20 and/or second port 30 may include sealed access ports that are similar to those that may be used for access ports 40. Similarly, they can include check valves such as those described herein.



FIGS. 3A and 4A illustrate cross-sectional views of the manifolds of FIGS. 1A and 2A, respectively. As illustrated, medical connectors 50′ can attach to the manifold at access ports 40′. Similar to medical connector 50 discussed above, medical connector 50′ can be a needleless medical connector that includes a connector body 60′, a connector base 70′, and a connector valve member 80′ positioned at least partially within the connector body 60′. In some embodiments, the manifolds 10′ and 10″″ shown in FIGS. 1A, 3A and 2A, 4A, respectively, can be modified to incorporate medical connectors 50.



FIGS. 3B and 4B illustrate cross-sectional views components of the manifolds shown FIGS. 1B and 2B, respectively. As illustrated, medical connectors 50′ can attach to the manifold at access ports 40′. In some embodiments, the manifolds 10″ and 10′″″ shown in FIGS. 1B, 3B and 2B, 4B, respectively, can be modified to incorporate medical connectors 50.


Medical connectors can be attached to the housings in a variety of ways. As shown in FIG. 4B for example, medical connector 50′ can incorporate features to facilitate sonic welding of the connector to the housing. In the illustrated embodiment, medical connector 50′ is attached to housing 12′″″ by way of connector base 70′. An inner recess in connector base 70′ is sized to receive projecting ring 44′ of access port 40′. Projecting ring can help stabilize medical connector 50′ on housing 12′″″.


Preferably, the medical connectors 50 can each provide a fluid flow path from a medical implement attached to the medical connector, through the medical connector, into the access port 40 and through an access channel 42 into a main channel 14 of the manifold. In a similar fashion, medical connectors 50′ can each provide a fluid flow path from a medical implement attached to the medical connector, through the medical connector, and into the access port 40′ and through an access channel 42′ into a main channel 14 of the manifold. Preferably, the access port 40 or 40′ can include a one-way valve or check valve 100, which can allow fluid to flow through the medical connector into the main channel 14, but prevent fluid from flowing from the main channel back into the medical connector. Various embodiments of a check valve 100 are described in more detail below.



FIG. 5 illustrates a perspective view of an access port 40 of a manifold. The access port can include a recess 140 with an outer wall 142 and a base 144. The recess is preferably cylindrical such that the outer wall is cylindrical, although in some embodiments it can have other shapes. An access channel 42 can connect the base 144 to a main channel of a manifold or other device. A plurality of protrusions 150 can extend upward from the base of the recess 140. The protrusions can each include a central wall 152 that faces the access channel 42, side walls 154, and an outer wall 156. In some embodiments, the central walls 152 of the protrusions can be flush with a side wall 43 of the access channel 42. In some embodiments, the central walls 152 can define a continuous surface with a side wall 43 of the access channel.


Preferably, the outer walls 156 of the protrusion do not extend all the way to the outer wall 142 of the access port recess 140, thereby defining an outer channel 48 between the protrusions and the outer wall 142. The protrusions can be spaced from each other to define transverse channels 46 between them that can connect the outer channel 48 to the access channel 42. In some embodiments, the access port 40 can also include an outer recess 44 that can be used to help seat a medical connector attached to the access port.



FIG. 5A illustrates a perspective view of an access port 40′ of a manifold which is similar in many respects to access port 40. The access port can include a recess 140′ with an outer wall 142′ and a base 144′. The recess is preferably cylindrical such that the outer wall is cylindrical, although in some embodiments it can have other shapes. An access channel 42′ can connect the base 144′ to a main channel of a manifold or other device. A plurality of protrusions 150′ can extend upward from the base of the recess 140′. The protrusions can each include a central wall 152′ that faces the access channel 42′ and side walls 154′. In some embodiments, the central walls 152′ of the protrusions can be recessed back from a side wall 43′ of the access channel 42′ as shown. The transition from the central walls 152′ to the side wall 43′ may be curved to facilitate fluid flow there through. In some embodiments, the central walls 152′ can define a continuous surface with a side wall 43′ of the access channel. As shown, the protrusions 150′ may be formed flush with the outer wall 142′ though in some embodiments, they may be off set from the wall and provide an outer fluid channel like channel 48 shown in FIG. 5. Access port 40′ may also include projecting ring 44′ that may be used to stabilize connector 50′ as shown.



FIG. 6 illustrates a top view of an access port 40. In the embodiment of FIG. 6, the access port includes four protrusions 150 that are spaced symmetrically about a center of the access channel 42. Preferably, side walls 154 of the protrusions are generally parallel to each other. In some embodiments, however, the side walls can angle toward each other as they get closer to the center of the access channel 42, and in some embodiments the side walls can diverge as they get closer toward the center of the access channel. In some embodiments, the access port 40 can include varying numbers of protrusions 50, such as 2, 3, 5, 6, or more protrusions. The protrusions can be symmetrically spaced about the access channel 42 or spaced about the access channel in other arrangements.


In some embodiments, various components of the access port 40 can be centered around the access channel 42. In some embodiments, the access channel itself can be generally cylindrical and have a radius R1, as illustrated. In some embodiments the outer wall 142 of the access port recess 140 can have a radius R3 centered on the center of the access channel 42. Similarly, the outer walls 156 of the protrusions 150 can be curved and have a radius of curvature R2 centered on the center of the access channel 42. Similar radius of curvatures may be defined by access port 40′. In the illustrated embodiment, R2′ and R3′ of access port 40′ would be equal.


When fluid flows through a medical connector attached to an access port 40, it will flow through the channels of the access port in order to reach a main channel of a fluid flow line. In various embodiments, the sizing of certain components of the access port can affect the size of the outer channel 48, transverse channels 46, and/or access channel 42, and therefore can affect the fluid flow characteristics of the access port 40.


Thus, for example, in some embodiments the ratio of the radius R3 of the access port recess 140 to the radius R2 of the outer walls 156 of protrusions 150 may vary. In some embodiments, the ratio of R3 to R2 can be between approximately 0.5 and 2.0. In some embodiments, the ratio of R3 to R2 can be between approximately 0.8 and 1.7. In some embodiments, the ratio of R3 to R2 can be between approximately 1.0 and 1.5. In some embodiments, the ratio of R3 to R2 can be between approximately 1.1 and 1.3. These ratios are also applicable to access port 40′.


Similarly, in some embodiments the ratio of the radius R3 of the access port recess 140 to the radius R1 of the access channel 42 may vary. In some embodiments, the ratio of R3 to R1 can be between approximately 2.0 and 3.3. In some embodiments, the ratio of R3 to R1 can be between approximately 2.3 and 3.0. In some embodiments, the ratio of R3 to R1 can be between approximately 2.5 and 2.8. In some embodiments, the ratio of R3 to R1 can be between approximately 2.6 and 2.7. These ratios are also applicable to access port 40′.


Further, in some embodiments the ratio of the radius R2 of the outer walls 156 of protrusions 150 to the radius R1 of the access channel 42 may vary. In some embodiments, the ratio of R2 to R1 can be between approximately 1.5 and 2.9. In some embodiments, the ratio of R2 to R1 can be between approximately 1.8 and 2.6. In some embodiments, the ratio of R2 to R1 can be between approximately 2.1 and 2.3. These ratios are also applicable to access port 40′.



FIGS. 7 and 8 illustrate perspective views of a check valve 100 that can be positioned within an access port 40 or 40′. FIG. 7 illustrates a bottom perspective view and FIG. 8 illustrates a top perspective view. The check valve preferably includes a diaphragm 110 having a bottom or lower surface 112, a side wall 114, and a top or upper surface 116. The diaphragm is preferably solid, although in some embodiments it can have perforations. A plurality of supports 120 can extend from the bottom or lower surface 112 of the diaphragm. The supports can be used to provide space for the diaphragm to flex from a closed to an open position, discussed in more detail below. Preferably, the diaphragm and supports are integrally formed (e.g., they may be molded as a single piece), although in some embodiments they may be formed of separate components.


The supports can have an outer wall 122 that is preferably flush with and forms a continuous surface with the side wall 114 of the diaphragm. In some embodiments, however, the supports 120 can be inset from the side wall 114 such that there is a portion of the bottom surface 112 between the supports 120 and the side wall 114.



FIG. 9 illustrates a bottom view of the valve 100. The valve is preferably circular with a radius R4, although in some embodiments the valve can have other shapes, such as a square, oval, rectangle, etc. In some embodiments, the radius R4 can be approximately equal to the radius R3 of the access port recess 140, such that the valve 100 can fit flush within the recess. In some embodiments, the radius R4 can be slightly or substantially smaller than the radius R3 such that a gap exists between the side walls 114 of the valve 100 and the side walls 142 of the access port recess when the valve is centered in the access port recess. The existence of a gap can make manufacturing of the valve easier. Varying the size of the gap can also affect flow rates through the valve. In some embodiments, the radius R4 can be between approximately 0.02 inches and approximately 0.09 inches smaller than the radius R3. In some embodiments, the radius R4 can be between approximately 0.03 inches and approximately 0.08 inches smaller than the radius R3. In some embodiments, the radius R4 can be between approximately 0.05 inches and approximately 0.06 inches smaller than the radius R3.


In some embodiments, as illustrated, the supports 120 can be positioned approximately 180 degrees apart about the center of the valve. The valve can have an axis of symmetry 2 that bisects the valve and does not pass through either support, as illustrated. In some embodiments, the valve can have more than two supports 120, with pairs positioned approximately 180 degrees apart from each other. For example, a valve could have four supports, each 90 degrees apart, and multiple axes of symmetry that bisect the valve and do not pass through any of the supports. In some embodiments, the axis of symmetry can define how the valve deforms if it experiences a pressure differential between its bottom surface 112 and its top surface 116. For example, in the illustrated embodiment, a positive net pressure on the top surface of the valve member would cause the valve member to bend, buckle, or curve generally about the axis of symmetry or an axis that is parallel to the axis of symmetry.


In some embodiments, the supports 120 can all be positioned the same minimum distance R5 from the center of the valve. In some embodiments, one or more of the supports can have a different minimum distance from the center of the valve than one or more of the other supports, in which case R5 can refer to the minimum distance from the center of the valve to the closest support 120. In some embodiments, the relationship between the distance R5 and R4 can affect how easily the valve member deforms as a result of differential pressures on the top surface 116 and bottom surface 112 of the diaphragm 110. In some embodiments, for example, the ratio of R4 to R5 can be between approximately 1.2 and approximately 1.8. In some embodiments, the ratio of R4 to R5 can be between approximately 1.3 and approximately 1.6. In some embodiments, the ratio of R4 to R5 can be between approximately 1.3 and approximately 1.5. In some embodiments, the ratio of R4 to R5 can be between approximately 1.35 and approximately 1.45. In some embodiments, the ratio of R4 to R5 can be greater than 1.8 or less than 1.2.



FIG. 10 illustrates a side view of the valve 100, oriented such that the axis of symmetry 2 is perpendicular to the illustrated plane. In various embodiments, the sizing of the diaphragm 110 and supports 120 can be modified to adjust the pressure differential required for the valve member to bend or buckle. For example, the supports can have a width w1 and the distance between the supports can have a width w2. Similarly, the diaphragm can have a thickness t1 and the supports can have a height h1. In some embodiments, the ratio of the width w2 to the thickness t1 can affect the ability of the valve to resist pressure differentials. In some embodiments, the ratio of the width w2 to the thickness t1 can be between approximately 7 and approximately 10. In some embodiments, the ratio of the width w2 to the thickness t1 can be between approximately 7.5 and approximately 9.5. In some embodiments, the ratio of the width w2 to the thickness t1 can be between approximately 8 and approximately 9. In some embodiments, the ratio of the width w2 to the thickness t1 can be between approximately 8.2 and approximately 8.5.


In some embodiments, the ratio of the width w2 to the height h1 of the supports can affect how easily and how much the diaphragm 110 can bend when the valve is in an open position, discussed below. This can also affect the ability of the valve to handle high flow rates and/or how quickly the valve opens to allow fluid flow. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 3 and approximately 8. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 4 and approximately 7. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 4.5 and approximately 6.5. In some embodiments, the ratio of the width w2 to the height h1 can be between approximately 5 and approximately 6.



FIG. 11A illustrates a valve 100 positioned within an access port 40, as described above. The supports 120 can be positioned on the protrusions 150 to lift the diaphragm above the protrusions. In some embodiments, the access port recess 140 can have no protrusions and the supports of the valve can be positioned directly on the base 144 of the recess or on the base of any recessed portion of a flow channel. Thus, for example, in some embodiments the valve can be positioned within an inlet and/or an outlet port of a manifold, extension set, or other connection systems. In some embodiments, the valve can be positioned within a medical connector that has only a single inlet and outlet port.



FIG. 11B illustrates a cross-sectional view of an access port 40 that has a medical connector attached to the access port. The access port can have a valve 100, which is not shown for illustrative purposes. As shown in FIG. 11B, when a medical connector is attached to an access port there can be a height h2 between a ring 74 of the medical connector and a top surface of the protrusions 150 extending from the base of the recess 140. There can also be a height h3 between a bottom surface of the base 70 of the medical connector (excluding any ring 74) and the top surface of the protrusions 150. Also visible in FIG. 11B is an inner radius R6 of the ring 74 of the medical connector (i.e., a radius from the center of the ring to an inner surface of a wall that forms the ring).



FIGS. 12A and 12B illustrate a cross-sectional view of an access port 40 that includes a valve member 100 and that has a medical connector 50 attached to the access port. In some embodiments, a base 70 of the medical connector can have an annular projection 72 that can be used to help attach the medical connector to the access port such as by sonic welding or gluing. Other forms of attachment are also possible, including snap fit constructions. In the illustrated embodiment, projection 72 is preferably glued into outer recess 44.



FIG. 12A illustrates the valve member 100 in a closed position and FIG. 12B illustrates the valve member in an open position. The valve is oriented the same as in FIG. 10, such that the axis of symmetry of the valve is perpendicular to the plane of the figure. In the closed position, the diaphragm 112 of the valve can be generally flat on both sides and can seal against the base 70 of the medical connector. In some embodiments, as illustrated, the medical connector can have a ring 74 or other projection that can be sized and configured to contact and seal against the diaphragm 110 of the valve 100 when the valve is in a closed position. As shown in FIG. 4B, medical connector 50′ may include a similar ring 74′.


In some embodiments, the medical connector 50 and/or the access port 40 can be sized and configured such that the base 70 of the medical connector or the ring 74 can compress at least a portion of the valve 100. This can help create the seal between the diaphragm 110 and the medical connector. Thus, in embodiments where the diaphragm seals against a ring 74 or other projection of the medical connector, the height h2 (shown in FIG. 11B) can be less than the total height of the valve member 100 (i.e., the sum of h1 and t1, illustrated in FIG. 10). Similarly, in embodiments where the connector does not have a ring or other projection, the height h3 (shown in FIG. 11B) can be less than the total height of the valve member. In various embodiments, the relative differences between the heights can affect the amount of sealing. For example, in some embodiments the ratio of the total height of the valve member to the height h2 can be between approximately 1.0 and approximately 1.5. In some embodiments, the ratio of the total height of the valve member to the height h2 can be between approximately 1.0 and approximately 1.3. In some embodiments, the ratio of the total height of the valve member to the height h2 can be between approximately 1.0 and approximately 1.2. In some embodiments, the ratio of the total height of the valve member to the height h2 can be between approximately 1.1 and approximately 1.2. In embodiments without a sealing ring 74 or other projection, various ratios of the total height of the valve member to the height h3 can be as described with respect to the height h2. In some embodiments, the total height of the valve member can be less than the height h2 such that the valve member functions as a floating check valve. In some such instances, the supports 120 on the bottom surface of the diaphragm 110 may provide stability and prevent inversion of the diaphragm. Similar ratios are applicable to medical connector 50′.


In various embodiments, the relationship between the radius R6 of a ring 74 (shown in FIG. 11B) and the distance R5 between supports 120 and the center of the valve (shown in FIG. 10) can affect how the valve deforms in response to a compressive force from the ring and any resulting change in a seal between the ring and the valve and/or in a cracking pressure of the valve (described further below). Preferably, R5 can be approximately equal to R6. In some embodiments, R5 can be smaller than R6. In some embodiments, R5 can be greater than R6. In some embodiments, the relationship between R5 and R6 can be varied according to the durometer of the check valve 100 in order to ensure that the valve seals as desired. Similar adjustments can be made to medical connector 50′.


If a negative pressure differential exists on the diaphragm between the bottom surface 112 and the upper or top surface 116—i.e., a net negative pressure on the top surface—the pressure will tend to push the diaphragm against the base 70 or inner annular projection 74, which can create or enhance a seal and prevent fluid from flowing into the medical connector. In contrast, if there is a positive pressure differential—i.e., a positive net pressure on the top surface 116—the diaphragm 110 will tend to deform as described above and move the valve from a closed to an open position, as illustrated in FIG. 12B. In the open position, the valve can flex downward (creating a concavity on its top surface), allowing fluid to flow through an opening 76 in the base of the medical connector, into the access port recess 140, and through the access channel 42 to reach the main channel 14.


In some embodiments, at least a portion of the valve member 100 remains stationary as the valve transitions between an open and closed position. This can help the valve move more easily from an open to a closed position to help prevent undesired retrograde flows. It can also allow for designs that transition from a closed to an open position at lower pressures, as described further below. In some embodiments, at least a portion of the diaphragm can remain in generally the same location when the valve is in an open position as when the valve is in a closed position. In some embodiments, at least a portion of the diaphragm 110 can remain in contact with the base 70 of a medical connector when the valve is in the open position.


In some embodiments, the valve 100 can be formed of a resilient material such that, absent a pressure differential, the valve tends to move toward the closed position (i.e., is biased toward the closed position).


As described above, the valve can be designed differently to affect how easily it moves from a closed to an open position. The pressure differential required to move the valve 100 from a closed to an open position can be referred to as the cracking pressure. In some embodiments, the valve can have a minimal cracking pressure, such that the valve very easily transitions from a closed to an open position. This can make it easier to pass fluids through the valve and into a main fluid flow line. It also allows the valves to work effectively with high flow rate connectors (such as, for example, connectors that allow flow rates of 450 mL/min or even greater). In some embodiments, the valve can have a cracking pressure that is at or below approximately 5 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 4 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 3 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 2 psi. In some embodiments, the valve can have a cracking pressure that is at or below approximately 1 psi. In some embodiments, the valve can have a cracking pressure that is less than the pressure exerted on the valve from fluid in a reservoir hanging on a standard IV pole. In some embodiments, this can be approximately equal to the pressure of 36 inches of water. In some embodiments, this can be approximately equal to 1.3 psi.


In some embodiments, the cracking pressure can be zero, such that even with zero pressure differential between the lower 112 and upper 116 surfaces of the diaphragm 110 the valve will be in an open position. In other words, in some embodiments the closed position of the valve is not an equilibrium position of the valve. In such embodiments, the valve may not be in a closed position until a retrograde fluid flow creates a negative pressure differential on the diaphragm 110. In some embodiments with a zero cracking pressure, the valve can function as a floating check valve, as described, for example, above.



FIGS. 13A and 13B illustrate a cross-sectional view of an access port 40 that includes a valve 100 and that has a medical connector attached to the access port. FIGS. 13A and 13B are similar to FIGS. 12A and 12B, but include an illustration of the entirety of a medical connector 50 that can be attached to the access port. Additionally, FIG. 13A illustrates the valve 100 in a closed position and FIG. 13B illustrates a medical implement 200 connected to the medical connector.


As described above, in some embodiments the medical connector 50 can be a needleless connector that has a base 70, a body 60, and a connector valve member 80. The base can also include an internal projection 90 that is within the body 60. A cannula 202 of the medical implement can compress the connector valve member 80 into an open position, exposing an opening 92 in the internal projection through which fluid in the cannula can pass. Once within the internal projection, the fluid can flow into the access port recess 140, through the access channel 42, and into the main flow channel 14. Similar activation can occur with medical connector 50′.


In some embodiments, one or more components of the devices and elements described herein can be translucent, transparent, and/or clear such that the fluid flow path through the components is visible. These components can include, for example, the housing 12 of a manifold, the medical connector 50 (including the body 60, base 70, and/or valve member 80), the medical connector 50′ (including the body 60′, base 70′, and/or valve member 80′), and/or the check valve 100. Additionally, in some embodiments one or more components can include elements configured or adapted to kill pathogens. For example, in some embodiments one or more of the valves 80, 80′, or 100 can include antimicrobial agents. In some embodiments, the antimicrobial agents can be a coating or can be incorporated into the structure of the components, from where they can leach out, such as from a silicone matrix of a valve.


The terms “approximately”, “about”, and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.


Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above.


Similarly, this method of disclosure is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, inventive aspects may lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.

Claims
  • 1. A medical check valve for use in a medical device to provide one-way fluid flow between a first fluid location and a second fluid location, said check valve comprising: a flexible diaphragm comprising a top surface, a bottom surface, and a side wall between the top surface and the bottom surface;a first support member extending from the bottom surface of the flexible diaphragm and a second support member extending from the bottom surface of the flexible diaphragm, the first support member and second support member positioned to define a line of symmetry that bisects the bottom surface without passing through the first support member or the second support member;wherein the flexible diaphragm has a first position in which the top surface is generally planar and is configured to seal against a fluid opening and a second position in which a portion of the diaphragm is curved between the first and second support members to form a concavity in the top surface about the line of symmetry and is configured to be displaced from the fluid opening.
  • 2. The medical check valve of claim 1, wherein the line of symmetry is the only line of symmetry that bisects the bottom surface without passing through the first support member or the second support member.
  • 3. The medical check valve of claim 1, wherein the flexible diaphragm is a disc.
  • 4. The medical check valve of claim 3, wherein the first and second support members are positioned 180 degrees apart about the disc.
  • 5. The medical check valve of claim 1, wherein the flexible diaphragm is nonperforate.
  • 6. The medical check valve of claim 1, wherein the flexible diaphragm, the first support member, and the second support member are integrally formed.
  • 7. The medical check valve of claim 1, wherein a net pressure of less than 3 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position.
  • 8. The medical check valve of claim 7, wherein a net pressure of less than 1 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position.
  • 9. The medical check valve of claim 8, wherein a positive net pressure on the bottom surface of the flexible diaphragm is needed to maintain the flexible diaphragm in the first position.
  • 10. The medical check valve of claim 1, wherein no support members other than the first and second support members extend from the bottom surface of the flexible diaphragm.
  • 11. A medical manifold comprising: a fluid channel;a port in fluid communication with said fluid channel, wherein the port is configured to be connected to a medical connector; anda check valve positioned in said port and comprising: a flexible diaphragm comprising a top surface, a bottom surface, and a side wall between the top surface and the bottom surface; anda first support member extending from the bottom surface of the flexible diaphragm and a second support member extending from the bottom surface of the flexible diaphragm, the first support member and second support member positioned to define a line of symmetry that bisects the bottom surface without passing through the first support member or the second support member;wherein the flexible diaphragm has a first position in which the top surface is generally planar and is configured to seal against a fluid opening in fluid communication with the medical connector when the medical connector is connected to the port and a second position in which the top surface of the diaphragm is curved around the line of symmetry and is configured to be displaced from the fluid opening; andwherein the first and second support members remain in generally the same location in said port when the flexible diaphragm is in the first and second positions.
  • 12. The medical manifold of claim 11, wherein the line of symmetry is the only line of symmetry that bisects the bottom surface without passing through the first support member or the second support member.
  • 13. The medical manifold of claim 11, wherein the flexible diaphragm is a disc.
  • 14. The medical manifold of claim 13, wherein the first and second support members are positioned 130 degrees apart about the disc.
  • 15. The medical manifold of claim 11, wherein the flexible diaphragm is nonperforated.
  • 16. The medical manifold of claim 11, wherein the flexible diaphragm, the first support member, and the second support member are integrally formed.
  • 17. The medical manifold of claim 11, wherein a net pressure of less than 3 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position.
  • 18. The medical manifold of claim 17, wherein a net pressure of less than 1 psi on the top surface of the flexible diaphragm is sufficient to move the diaphragm from the first position to the second position.
  • 19. The medical manifold of claim 18, wherein a positive net pressure on the bottom surface of the flexible diaphragm is needed to maintain the flexible diaphragm in the first position.
  • 20. The medical manifold of claim 11, wherein no support members other than the first and second support members extend from the bottom surface of the flexible diaphragm.
RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/179,760, filed Jun. 10, 2016, titled MEDICAL FLUID MANIFOLD, which is a continuation of PCT/US2014/068455, filed Dec. 3, 2014, titled CHECK VALVE, which claims the benefit of U.S. Provisional Application No. 61/914,892, filed Dec. 11, 2013, titled CHECK VALVE, the entire contents of each are incorporated by reference herein and made a part of this specification.

US Referenced Citations (983)
Number Name Date Kind
274447 Kennish Mar 1883 A
724445 Decker Apr 1903 A
1578517 Hein Mar 1926 A
1923501 Perry Aug 1933 A
2210098 Ravenscroft Aug 1940 A
2289677 Perelson Jul 1942 A
2347988 Burke Oct 1943 A
2577780 Lockhart Dec 1951 A
2688979 Kendrick Sep 1954 A
2756282 Deane Jul 1956 A
2756740 Deane Jul 1956 A
2809665 Crowe Oct 1957 A
2847995 Adams Aug 1958 A
2999499 Willet Sep 1961 A
3134380 Armao May 1964 A
3135261 Carroll Jun 1964 A
3171412 Braun Mar 1965 A
3176021 Volungis et al. Mar 1965 A
3191655 McCord Jun 1965 A
3193154 Brass et al. Jul 1965 A
3334860 Bolton, Jr. Aug 1967 A
3352531 Kilmarx Nov 1967 A
3354881 Bloch Nov 1967 A
3385301 Harautuneian May 1968 A
3502097 Muller Mar 1970 A
3534771 Eyerdam et al. Oct 1970 A
3570484 Steer et al. Mar 1971 A
3630199 Gangarosa Dec 1971 A
3648684 Barnwell et al. Mar 1972 A
3659602 Cloyd May 1972 A
3693651 Gifford Sep 1972 A
3717174 Dewall Feb 1973 A
3726282 Patel Apr 1973 A
26939 Ballard Oct 1973 A
3788519 Mengel Jan 1974 A
3830241 Dye et al. Aug 1974 A
3831629 Mackal et al. Aug 1974 A
3852385 Huggins Dec 1974 A
3861388 Vaughn Jan 1975 A
3889675 Stewart Jun 1975 A
3896853 Bernhard Jul 1975 A
D237882 Yamasaki Dec 1975 S
3965910 Fisher Jun 1976 A
3974832 Kruck Aug 1976 A
3976063 Henneman et al. Aug 1976 A
3976073 Quick et al. Aug 1976 A
3977403 Patel Aug 1976 A
3986508 Barrington Oct 1976 A
3993063 Larrabee Nov 1976 A
3994293 Ferro Nov 1976 A
4005710 Zeddies Feb 1977 A
4019512 Tenczar Apr 1977 A
4022205 Tenczar May 1977 A
4040420 Speer Aug 1977 A
4076285 Martinez Feb 1978 A
4079738 Dunn et al. Mar 1978 A
4080965 Phillips Mar 1978 A
4121585 Becker, Jr. Oct 1978 A
4128098 Bloom et al. Dec 1978 A
4133441 Mittleman et al. Jan 1979 A
4143853 Abramson Mar 1979 A
4149535 Volder Apr 1979 A
4161949 Thanawalla Jul 1979 A
4186775 Muroi Feb 1980 A
4187846 Lolachi et al. Feb 1980 A
4191183 Mendelson Mar 1980 A
4198983 Becker et al. Apr 1980 A
4200096 Charvin Apr 1980 A
4214779 Losell Jul 1980 A
4219912 Adams Sep 1980 A
4243034 Brandt Jan 1981 A
4244378 Brignola Jan 1981 A
4257416 Prager Mar 1981 A
D259278 McCaw et al. May 1981 S
4294249 Sheehan et al. Oct 1981 A
4294250 Dennehey Oct 1981 A
4296949 Muetterties et al. Oct 1981 A
4306705 Svensson Dec 1981 A
D263871 Matsuura Apr 1982 S
4324239 Gordon et al. Apr 1982 A
4328802 Curley et al. May 1982 A
4329987 Rogers et al. May 1982 A
4334551 Pfister Jun 1982 A
4338933 Bayard et al. Jul 1982 A
4342315 Jackson Aug 1982 A
4346703 Dennehey et al. Aug 1982 A
4362156 Feller et al. Dec 1982 A
4387879 Tauschinski Jun 1983 A
RE31315 Jenkins et al. Jul 1983 E
4392851 Elias Jul 1983 A
4405163 Voges et al. Sep 1983 A
4405312 Gross et al. Sep 1983 A
4411662 Pearson Oct 1983 A
4417890 Dennehey et al. Nov 1983 A
4421296 Stephens Dec 1983 A
4429856 Jackson Feb 1984 A
4432759 Gross et al. Feb 1984 A
4432765 Oscarsson Feb 1984 A
4434810 Atkinson Mar 1984 A
4439188 Dennehey et al. Mar 1984 A
4439193 Larkin Mar 1984 A
4449693 Gerea May 1984 A
4457749 Bellotti et al. Jul 1984 A
4483368 Panthafer Nov 1984 A
4508367 Oreopoulos et al. Apr 1985 A
4511359 Vaillancourt Apr 1985 A
4512766 Vaillancourt Apr 1985 A
4535818 Duncan et al. Aug 1985 A
4535820 Raines Aug 1985 A
4556086 Raines Dec 1985 A
4564054 Gustavsson Jan 1986 A
4566480 Parham Jun 1986 A
4592356 Guiterrez Jun 1986 A
4607868 Harvey et al. Aug 1986 A
4610469 Wolff-Mooij Sep 1986 A
4617012 Vaillancourt Oct 1986 A
4619640 Poholshy et al. Oct 1986 A
4621654 Holter Nov 1986 A
4623068 Brown et al. Nov 1986 A
4645494 Lee et al. Feb 1987 A
4666429 Stone May 1987 A
D290656 Kaleskas Jun 1987 S
4673400 Martin Jun 1987 A
4676228 Krasner et al. Jun 1987 A
4683916 Raines Aug 1987 A
4706487 Bandou et al. Nov 1987 A
4710168 Schwab et al. Dec 1987 A
4725267 Vaillancourt Feb 1988 A
4730635 Linden Mar 1988 A
4752292 Lopez et al. Jun 1988 A
D296592 Wellenstam Jul 1988 S
4758224 Siposs Jul 1988 A
4759756 Forman et al. Jul 1988 A
4775369 Schwartz Oct 1988 A
4778447 Velde et al. Oct 1988 A
4778453 Lopez Oct 1988 A
4781702 Herrli Nov 1988 A
4804015 Albinsson Feb 1989 A
D300177 Bellotti et al. Mar 1989 S
D300361 Tokarz Mar 1989 S
4810241 Rogers et al. Mar 1989 A
4813938 Raulerson Mar 1989 A
4819684 Zaugg et al. Apr 1989 A
4832214 Schrader et al. May 1989 A
4834664 Lin May 1989 A
4834716 Ogle, II May 1989 A
D303013 Konopka Aug 1989 S
4871353 Thomsen Oct 1989 A
4874377 Newgard et al. Oct 1989 A
4878897 Katzin Nov 1989 A
4880414 Whipple Nov 1989 A
4883456 Holter Nov 1989 A
4889527 Herrli Dec 1989 A
4908018 Thomsen Mar 1990 A
4915687 Sivert Apr 1990 A
4917668 Haindl Apr 1990 A
4919167 Manska Apr 1990 A
4928212 Benavides May 1990 A
4934657 Dodson Jun 1990 A
4943896 Johnson Jul 1990 A
4946445 Lynn Aug 1990 A
4946448 Richmond Aug 1990 A
4963133 Whipple Oct 1990 A
4964855 Todd et al. Oct 1990 A
4966199 Ruschke Oct 1990 A
4969883 Gilbert et al. Nov 1990 A
D314050 Sone Jan 1991 S
4985399 Matsuda et al. Jan 1991 A
4987181 Bichon et al. Jan 1991 A
4991413 Arnalda Feb 1991 A
4991629 Ernesto et al. Feb 1991 A
4991745 Brown Feb 1991 A
4995863 Nichols et al. Feb 1991 A
4998713 Vaillancourt Mar 1991 A
4998927 Vaillancourt Mar 1991 A
5006114 Rogers et al. Apr 1991 A
5009490 Kuono et al. Apr 1991 A
5018532 Ethridge, III May 1991 A
5024657 Needham et al. Jun 1991 A
5030210 Alchas Jul 1991 A
5031675 Lindqren Jul 1991 A
5041087 Loo et al. Aug 1991 A
5046456 Heyman et al. Sep 1991 A
5049128 Duquette Sep 1991 A
D321250 Jepson et al. Oct 1991 S
D321251 Jepson et al. Oct 1991 S
5061253 Yoshida Oct 1991 A
5064416 Newgard Nov 1991 A
5065783 Ogle, II Nov 1991 A
5071411 Hillstead Dec 1991 A
5098385 Walsh Mar 1992 A
5098405 Peterson et al. Mar 1992 A
5098406 Sawyer Mar 1992 A
5100394 Dudar et al. Mar 1992 A
5108380 Heritze et al. Apr 1992 A
5114408 Fleischhaker et al. May 1992 A
5116361 Kim et al. May 1992 A
5122123 Vaillancourt Jun 1992 A
5125915 Berry et al. Jun 1992 A
5135489 Jepson et al. Aug 1992 A
5137524 Lynn et al. Aug 1992 A
5147333 Raines Sep 1992 A
5154703 Bonaldo Oct 1992 A
5156600 Young Oct 1992 A
5158554 Jepson et al. Oct 1992 A
5163922 McElveen, Jr. et al. Nov 1992 A
5167238 Newman Dec 1992 A
5167636 Clement Dec 1992 A
5171234 Jepson et al. Dec 1992 A
5180761 Shiao Jan 1993 A
5188620 Jepson et al. Feb 1993 A
5190067 Paradis et al. Mar 1993 A
5199947 Lopez et al. Apr 1993 A
5201717 Wyatt et al. Apr 1993 A
5201722 Moorehead et al. Apr 1993 A
5203775 Frank et al. Apr 1993 A
5211638 Dudar et al. May 1993 A
5215538 Larkin Jun 1993 A
5221271 Nicholson et al. Jun 1993 A
5224515 Foster et al. Jul 1993 A
5242393 Brimhall et al. Sep 1993 A
5242423 Goodsir et al. Sep 1993 A
5242425 White et al. Sep 1993 A
5242432 DeFrank Sep 1993 A
5249598 Schmidt Oct 1993 A
5251873 Atkinson et al. Oct 1993 A
5253842 Huebscher et al. Oct 1993 A
5255676 Russo Oct 1993 A
5256155 Yerlikaya et al. Oct 1993 A
5267966 Paul Dec 1993 A
5269771 Thomas et al. Dec 1993 A
5273533 Bonaldo Dec 1993 A
5280876 Atkins Jan 1994 A
D344585 Morse Feb 1994 S
5284475 Mackal Feb 1994 A
5290254 Vaillancourt Mar 1994 A
5292308 Ryan Mar 1994 A
5293902 Lapierie Mar 1994 A
5295657 Atkinson Mar 1994 A
5295658 Atkinson et al. Mar 1994 A
D346011 Hawkins Apr 1994 S
5301686 Newman Apr 1994 A
5306265 Ragazzi Apr 1994 A
5312083 Ekman May 1994 A
5312377 Dalhon May 1994 A
5322518 Schneider Jun 1994 A
5324270 Kayon et al. Jun 1994 A
5336192 Palestrant Aug 1994 A
5342316 Wallace Aug 1994 A
5342326 Peppel et al. Aug 1994 A
5344414 Lopez et al. Sep 1994 A
5348542 Ellis Sep 1994 A
5353837 Faust Oct 1994 A
5356375 Higley Oct 1994 A
5356396 Wyatt et al. Oct 1994 A
5360413 Leason et al. Nov 1994 A
5380306 Brinon Jan 1995 A
5389086 Attermeier et al. Feb 1995 A
5391150 Richmond Feb 1995 A
5398530 Derman Mar 1995 A
5401245 Haining Mar 1995 A
D357736 Dye Apr 1995 S
5402826 Molnar et al. Apr 1995 A
5402982 Atkinson et al. Apr 1995 A
5407437 Heimreid Apr 1995 A
5409471 Atkinson et al. Apr 1995 A
5395348 Ryan May 1995 A
5411483 Loomas et al. May 1995 A
5411499 Dudar et al. May 1995 A
5417673 Gordon May 1995 A
5439451 Collinson et al. Aug 1995 A
5439452 McCarty Aug 1995 A
5441487 Vedder Aug 1995 A
5442941 Kahonen et al. Aug 1995 A
5453097 Paradis Sep 1995 A
5456676 Nelson et al. Oct 1995 A
5462255 Rosen et al. Oct 1995 A
D363988 Dye Nov 1995 S
D364459 Dye Nov 1995 S
D364460 Dye Nov 1995 S
D364680 Dye Nov 1995 S
5465938 Werge et al. Nov 1995 A
5470319 Mayer Nov 1995 A
5474544 Lynn Dec 1995 A
5480393 Bommarito Jan 1996 A
5487731 Denton Jan 1996 A
D367714 Pennicook Mar 1996 S
5501426 Atkinson et al. Mar 1996 A
5501526 Asai et al. Mar 1996 A
D368737 Dunn et al. Apr 1996 S
5509433 Paradis Apr 1996 A
5514116 Vaillancourt et al. May 1996 A
5520665 Fleetwood May 1996 A
5522804 Lynn Jun 1996 A
5533708 Atkinson et al. Jul 1996 A
5533996 Murphey et al. Jul 1996 A
5535771 Purdy et al. Jul 1996 A
5535785 Werge et al. Jul 1996 A
5540661 Tomisaka et al. Jul 1996 A
5549566 Elias et al. Aug 1996 A
5549577 Siegel et al. Aug 1996 A
5549651 Lynn Aug 1996 A
D373633 La Motte Sep 1996 S
5554136 Luther Sep 1996 A
5555908 Edwards et al. Sep 1996 A
5556388 Johlin, Jr. Sep 1996 A
5562632 Davila et al. Oct 1996 A
5569235 Ross et al. Oct 1996 A
5573516 Tyner Nov 1996 A
5577706 King Nov 1996 A
5578059 Patzer Nov 1996 A
5597536 Mayer Jan 1997 A
5674206 Allton et al. Jan 1997 A
5603706 Wyatt et al. Feb 1997 A
5609584 Gettig et al. Mar 1997 A
5616129 Mayer Apr 1997 A
5616130 Mayer Apr 1997 A
5617897 Myers Apr 1997 A
5620424 Abramson Apr 1997 A
5620434 Brony Apr 1997 A
5624414 Boettger Apr 1997 A
5632735 Wyatt et al. May 1997 A
5639810 Smith, III et al. Jun 1997 A
5645538 Richmond Jul 1997 A
5660205 Epstein Aug 1997 A
5667500 Palmer et al. Sep 1997 A
5669891 Vaillancourt Sep 1997 A
5676346 Leinsing Oct 1997 A
5685866 Lopez Nov 1997 A
5690612 Lopez et al. Nov 1997 A
5690865 Kindt-Larsen et al. Nov 1997 A
5694686 Lopez Dec 1997 A
5695466 Lopez et al. Dec 1997 A
5699821 Paradis Dec 1997 A
5700248 Lopez Dec 1997 A
5728751 Patnaik Mar 1998 A
5730418 Feith et al. Mar 1998 A
5738663 Lopez Apr 1998 A
5749861 Guala et al. May 1998 A
D394898 Evans Jun 1998 S
5769825 Lynn Jun 1998 A
5775671 Cote, Sr. Jul 1998 A
5776113 Daugherty et al. Jul 1998 A
5782816 Werschmidt et al. Jul 1998 A
5785693 Haining Jul 1998 A
5788215 Ryan Aug 1998 A
5797897 Jepson et al. Aug 1998 A
5806551 Meloul et al. Sep 1998 A
5806831 Paradis Sep 1998 A
5807348 Zinger et al. Sep 1998 A
5810789 Powers et al. Sep 1998 A
D400263 Shugart Oct 1998 S
5817068 Urrutia Oct 1998 A
5817069 Arnett Oct 1998 A
5820601 Mayer Oct 1998 A
5833213 Ryan Nov 1998 A
5836923 Mayer Nov 1998 A
5839715 Leinsing Nov 1998 A
5843044 Moorehead Dec 1998 A
5843046 Motisi et al. Dec 1998 A
5846233 Lilley et al. Dec 1998 A
5865807 Blake, III Feb 1999 A
5873862 Lopez Feb 1999 A
5882348 Winterton et al. Mar 1999 A
5899888 Jepson et al. May 1999 A
5901942 Lopez May 1999 A
5911710 Barry et al. Jun 1999 A
5928204 Lopez Jul 1999 A
5935620 Baudin Aug 1999 A
5947954 Bonaldo Sep 1999 A
5954313 Ryan Sep 1999 A
5957898 Jepson et al. Sep 1999 A
5967490 Pike Oct 1999 A
5979868 Wu et al. Nov 1999 A
5984903 Nadal Nov 1999 A
D418916 Bastable Jan 2000 S
6009902 Troiani et al. Jan 2000 A
6019748 Lopez Feb 2000 A
6029946 Doyle Feb 2000 A
6036171 Weinheimer et al. Mar 2000 A
6039302 Cote, Sr. et al. Mar 2000 A
6048335 Mayer Apr 2000 A
6050978 Orr et al. Apr 2000 A
6063062 Paradis May 2000 A
6079432 Paradis Jun 2000 A
6089541 Weinheier et al. Jul 2000 A
6099511 Devos et al. Aug 2000 A
6113068 Ryan Sep 2000 A
6116571 Hettinger Sep 2000 A
6117114 Paradis Sep 2000 A
6132403 Lopez Oct 2000 A
6132404 Lopez Oct 2000 A
6142446 Leinsing Nov 2000 A
6152900 Mayer Nov 2000 A
6162206 Bindokas et al. Dec 2000 A
6162251 Kredovski Dec 2000 A
6168137 Paradis Jan 2001 B1
6170800 Meloul et al. Jan 2001 B1
6171287 Lynn Jan 2001 B1
6177037 Mayer Jan 2001 B1
6183448 Mayer Feb 2001 B1
6189859 Rohrbough et al. Feb 2001 B1
D438955 Rudzena Mar 2001 S
6206861 Mayer Mar 2001 B1
6210624 Mayer Apr 2001 B1
6213996 Jepson et al. Apr 2001 B1
6228065 Lynn May 2001 B1
6228069 Barth et al. May 2001 B1
6245048 Fangrow et al. Jun 2001 B1
6254579 Cogger et al. Jul 2001 B1
6261282 Jepson et al. Jul 2001 B1
6261630 Nazarova et al. Jul 2001 B1
6279783 Brown et al. Aug 2001 B1
6290206 Doyle Sep 2001 B1
6299131 Ryan Oct 2001 B1
6299132 Wienheimer Oct 2001 B1
6325782 Lopez Dec 2001 B1
D454637 Netenborg Mar 2002 S
6364861 Feith et al. Apr 2002 B1
6364869 Bonaldo Apr 2002 B1
6390130 Guala May 2002 B1
6428520 Lopez et al. Aug 2002 B1
6444324 Yang et al. Sep 2002 B1
6482188 Rogers et al. Nov 2002 B1
D468015 Horppu Dec 2002 S
D468016 Mosler et al. Dec 2002 S
6530504 Socier Mar 2003 B2
6541802 Doyle Apr 2003 B2
6543745 Enerson Apr 2003 B1
D475795 Johnson et al. Jun 2003 S
6572592 Lopez Jun 2003 B1
6585229 Cote, Sr. et al. Jul 2003 B2
6595964 Finley et al. Jul 2003 B2
6595981 Huet Jul 2003 B2
6599273 Lopez Jul 2003 B1
6605076 Jepson et al. Aug 2003 B1
6609696 Enerson Aug 2003 B2
6635044 Lopez Oct 2003 B2
6651956 Miller Nov 2003 B2
6656517 Michal et al. Dec 2003 B2
6669673 Lopez Dec 2003 B2
6669681 Jepson et al. Dec 2003 B2
6673053 Wang et al. Jan 2004 B2
6682509 Lopez Jan 2004 B2
6689109 Lynn Feb 2004 B2
6695817 Fangrow, Jr. Feb 2004 B1
6706022 Leinsing et al. Mar 2004 B1
6712791 Lui et al. Mar 2004 B2
6727294 Kanayama et al. Apr 2004 B2
6740063 Lynn May 2004 B2
6745998 Doyle Jun 2004 B2
6755391 Newton et al. Jun 2004 B2
6758833 Lopez Jul 2004 B2
6783709 Harreld et al. Aug 2004 B2
6802490 Leinsing Oct 2004 B2
6808161 Hishikawa Oct 2004 B1
6832994 Niedospial, Jr. et al. Dec 2004 B2
6840501 Doyle Jan 2005 B2
6848139 Simon et al. Feb 2005 B2
6866656 Tingey et al. Mar 2005 B2
6869426 Ganem Mar 2005 B2
6871838 Raines et al. Mar 2005 B2
6883778 Newton et al. Apr 2005 B1
6892998 Newton May 2005 B2
6908459 Harding et al. Jun 2005 B2
6916309 Fangrow, Jr. Jul 2005 B2
6932795 Lopez et al. Aug 2005 B2
6964406 Doyle Nov 2005 B2
6991215 Kiehne Jan 2006 B2
6994315 Ryan et al. Feb 2006 B2
6997917 Niedospial, Jr. et al. Feb 2006 B2
7014169 Newton et al. Mar 2006 B2
7025744 Utterberg et al. Apr 2006 B2
7033339 Lynn Apr 2006 B1
7037302 Vaillancourt May 2006 B2
7044441 Doyle May 2006 B2
7074216 Fowles et al. Jul 2006 B2
7100890 Cote et al. Sep 2006 B2
7104520 Leinsing et al. Sep 2006 B2
7114701 Peppel Oct 2006 B2
7125396 Leinsing et al. Oct 2006 B2
7140592 Phillips et al. Nov 2006 B2
7184825 Leinsing et al. Feb 2007 B2
D546946 Blake Jul 2007 S
D547862 Dikeman et al. Jul 2007 S
7244249 Leinsing et al. Jul 2007 B2
7252652 Moorehead et al. Aug 2007 B2
7264859 Souns et al. Sep 2007 B2
D557281 Miller et al. Dec 2007 S
D557283 Miller et al. Dec 2007 S
7306197 Parrino et al. Dec 2007 B2
7306199 Leinsing et al. Dec 2007 B2
7314061 Peppel Jan 2008 B2
7326188 Russell et al. Feb 2008 B1
7329249 Bonaldo Feb 2008 B2
7335182 Hilaire Feb 2008 B1
D567941 Dikeman et al. Apr 2008 S
7357792 Newton et al. Apr 2008 B2
D568466 Dikeman et al. May 2008 S
D569391 Miller et al. May 2008 S
D569506 Dikeman et al. May 2008 S
D570880 Miller et al. Jun 2008 S
7396348 Newton et al. Jul 2008 B2
7422369 Bergman et al. Sep 2008 B2
7470261 Lynn Dec 2008 B2
7470262 Hiejima et al. Dec 2008 B2
7497848 Leinsing et al. Mar 2009 B2
7497849 Fangrow, Jr. Mar 2009 B2
7510545 Peppel Mar 2009 B2
7520489 Rushke Apr 2009 B2
7530546 Ryan et al. May 2009 B2
7533696 Paul, Jr. May 2009 B2
7556060 Guala Jul 2009 B2
7559530 Korogi et al. Jul 2009 B2
7563243 Mendels Jul 2009 B2
7581561 Funamura et al. Sep 2009 B2
7584767 Funamura et al. Sep 2009 B2
7588563 Guala Sep 2009 B2
7591449 Raines et al. Sep 2009 B2
7600530 Truitt et al. Oct 2009 B2
7601141 Dikeman et al. Oct 2009 B2
7615035 Peppel Nov 2009 B2
7624749 Guala Dec 2009 B2
7625359 Guala Dec 2009 B2
7628774 Fangrow, Jr. Dec 2009 B2
7645274 Whitley Jan 2010 B2
7651481 Raybuck Jan 2010 B2
7666170 Guala Feb 2010 B2
7673653 Mijers et al. Mar 2010 B2
7691090 Belley et al. Apr 2010 B2
7703486 Costanzo Apr 2010 B2
7713250 Harding et al. May 2010 B2
7717882 Harding May 2010 B2
7717886 Lopez May 2010 B2
7743799 Mosier et al. Jun 2010 B2
7753338 Desecki Jul 2010 B2
7753892 Newton et al. Jul 2010 B2
7758566 Simpson et al. Jul 2010 B2
7763013 Baldwin et al. Jul 2010 B2
7763199 Fangrow Jul 2010 B2
7771383 Truitt et al. Aug 2010 B2
7784766 Guala Aug 2010 B2
7806873 Dikeman et al. Oct 2010 B2
7815168 Vangsness et al. Oct 2010 B2
7824393 Fangrow, Jr. Nov 2010 B2
7837658 Cote, Sr. et al. Nov 2010 B2
7841581 Thorne, Jr. et al. Nov 2010 B2
7842026 Cahill et al. Nov 2010 B2
7857284 Kimball et al. Dec 2010 B2
7857285 Lee et al. Dec 2010 B2
7857802 Brandenburger et al. Dec 2010 B2
7857805 Raines Dec 2010 B2
7862537 Zinger et al. Jan 2011 B2
7867204 Bartholomew et al. Jan 2011 B2
7879012 Kane et al. Feb 2011 B2
7879013 Smith et al. Feb 2011 B2
7900659 Whitley et al. Mar 2011 B2
7905873 Rondeau et al. Mar 2011 B2
7909056 Truitt et al. Mar 2011 B2
7914502 Newton et al. Mar 2011 B2
D638933 Hill May 2011 S
7947032 Harding et al. May 2011 B2
7954515 Gerst Jun 2011 B2
7959614 Dikeman et al. Jun 2011 B2
7967797 Winsor et al. Jun 2011 B2
7975722 Kiehne Jul 2011 B2
7981090 Plishka et al. Jul 2011 B2
7981381 Lurvey et al. Jul 2011 B2
7984730 Ziv et al. Jul 2011 B2
7985206 Dikeman et al. Jul 2011 B2
D643920 Gil Pascual Aug 2011 S
7988128 Wentling Aug 2011 B2
7993328 Whitley Aug 2011 B2
7998122 Lynn et al. Aug 2011 B2
7998134 Fangrow Aug 2011 B2
8006953 Bennett Aug 2011 B2
D644731 Fang, Jr. Sep 2011 S
8015990 Pascal et al. Sep 2011 B2
8021354 Huang Sep 2011 B2
8034021 Mendels Oct 2011 B2
8034035 Weaver et al. Oct 2011 B2
8038663 Miner Oct 2011 B2
8042838 Buckler et al. Oct 2011 B2
8048038 Guala Nov 2011 B2
8052648 Dikeman et al. Nov 2011 B2
8057442 Dikeman et al. Nov 2011 B2
8062266 McKinnon et al. Nov 2011 B2
8062267 McKinnon et al. Nov 2011 B2
8062280 Jepson et al. Nov 2011 B2
8066648 Mark Nov 2011 B1
8066669 Christensen et al. Nov 2011 B2
8066670 Cluff et al. Nov 2011 B2
8070189 Yow et al. Dec 2011 B2
8070725 Christensen Dec 2011 B2
8074964 Mansour et al. Dec 2011 B2
8092432 Nordgren Jan 2012 B2
8096525 Ryan Jan 2012 B2
8100868 Newton et al. Jan 2012 B2
8100869 Vangsness et al. Jan 2012 B2
8105314 Fangrow Jan 2012 B2
D654166 Lair Feb 2012 S
D655000 Mirigian Feb 2012 S
8122923 Kraus et al. Feb 2012 B2
8123738 Vaillancourt Feb 2012 B2
8133209 Guala Mar 2012 B2
8136330 Ostler et al. Mar 2012 B2
8137303 Stout et al. Mar 2012 B2
8142403 Carlyon Mar 2012 B2
8152790 Lopez et al. Apr 2012 B2
8156971 Costanzo Apr 2012 B2
8157784 Rogers Apr 2012 B2
8162006 Guala Apr 2012 B2
8162013 Rosenquist et al. Apr 2012 B2
8162914 Kraushaar et al. Apr 2012 B2
8167863 Yow May 2012 B2
8172823 Rondeau et al. May 2012 B2
8177760 Rome et al. May 2012 B2
8177768 Leinsing May 2012 B2
8177772 Christensen et al. May 2012 B2
8182452 Mansour et al. May 2012 B2
8197452 Harding et al. Jun 2012 B2
8197466 Yokota et al. Jun 2012 B2
8211089 Winsor et al. Jul 2012 B2
8221363 Jepson Jul 2012 B2
8221391 Fangrow, Jr. Jul 2012 B2
8235971 Christensen et al. Aug 2012 B2
8241268 Whitley Aug 2012 B2
8277424 Pan Oct 2012 B2
8286657 Belley et al. Oct 2012 B2
8286936 Kitani et al. Oct 2012 B2
8287518 Kitani et al. Oct 2012 B2
8298195 Peppel Oct 2012 B2
8298196 Mansour Oct 2012 B1
8328769 Dikeman et al. Dec 2012 B2
8337483 Harding et al. Dec 2012 B2
8361408 Lynn Jan 2013 B2
8366658 Davis et al. Feb 2013 B2
8366676 Harding et al. Feb 2013 B2
8372043 Grimm et al. Feb 2013 B2
8377010 Harding et al. Feb 2013 B2
8382741 Chelak Feb 2013 B2
8398598 Carlyon et al. Mar 2013 B2
8398607 Fangrow, Jr. Mar 2013 B2
8403886 Bialecki et al. Mar 2013 B2
8403894 Lynn et al. Mar 2013 B2
8403905 Yow Mar 2013 B2
8408226 Raines et al. Apr 2013 B2
8409164 Fangrow Apr 2013 B2
8409165 Niedospial, Jr. et al. Apr 2013 B2
8414542 Stroup Apr 2013 B2
8439880 Rondeau May 2013 B2
8444628 Fangrow, Jr. May 2013 B2
8454579 Fangrow, Jr. Jun 2013 B2
8511352 Kraus et al. Aug 2013 B2
8512307 Fangrow Aug 2013 B2
8529524 Newton et al. Sep 2013 B2
8540692 Fangrow Sep 2013 B2
8551037 Suchecki et al. Oct 2013 B2
8568371 Slopes et al. Oct 2013 B2
8591476 Winsor et al. Nov 2013 B2
8628515 Fangrow, Jr. et al. Jan 2014 B2
8628516 Naftalovitz et al. Jan 2014 B2
8636720 Truitt et al. Jan 2014 B2
8640725 Truitt et al. Feb 2014 B2
8671964 Py Mar 2014 B2
8679090 Anderson et al. Mar 2014 B2
8684994 Lev et al. Apr 2014 B2
8701696 Guala Apr 2014 B2
8702675 Imai Apr 2014 B2
8715222 Truitt et al. May 2014 B2
8715247 Mansour et al. May 2014 B2
8721627 Albert May 2014 B2
D707355 Bow Jun 2014 S
8747370 Feith et al. Jun 2014 B2
8757590 Naftalovitz et al. Jun 2014 B2
8758306 Lopez et al. Jun 2014 B2
8801678 Panian et al. Aug 2014 B2
8808254 Lynn Aug 2014 B2
8814849 Winsor Aug 2014 B1
8834432 Winsor et al. Sep 2014 B2
8840577 Zollinger et al. Sep 2014 B1
8864725 Ranalletta et al. Oct 2014 B2
8870846 Davis et al. Oct 2014 B2
8870850 Fangrow, Jr. Oct 2014 B2
8876784 Cote, Sr. et al. Nov 2014 B2
8882742 Dikeman et al. Nov 2014 B2
8910919 Bonnal et al. Dec 2014 B2
8945084 Warren et al. Feb 2015 B2
8951233 Mansour Feb 2015 B2
8968261 Kimball et al. Mar 2015 B2
8968271 Guala Mar 2015 B2
8974425 Tachizaki et al. Mar 2015 B2
8974433 Fangrow Mar 2015 B2
8979804 Ho et al. Mar 2015 B2
8992501 Seifert et al. Mar 2015 B2
9005179 Fangrow et al. Apr 2015 B2
9005180 Seifert et al. Apr 2015 B2
9017295 Pan Apr 2015 B2
9032997 Abura et al. May 2015 B2
9039047 Imai May 2015 B2
9044585 Masuda et al. Jun 2015 B2
9060921 Seifert et al. Jun 2015 B2
9061130 Truitt et al. Jun 2015 B2
9067049 Panian et al. Jun 2015 B2
D734456 Cromett Jul 2015 S
9072657 Seifert et al. Jul 2015 B2
9089680 Ueda et al. Jul 2015 B2
9089681 Ueda et al. Jul 2015 B2
9089682 Yeh et al. Jul 2015 B2
D737436 Lev Aug 2015 S
9107809 Garfield et al. Aug 2015 B2
9108034 Winsor Aug 2015 B2
9114244 Yeh et al. Aug 2015 B2
9119950 Mansour et al. Sep 2015 B2
9138572 Zeytoonian et al. Sep 2015 B2
9144672 Mansour et al. Sep 2015 B2
9162029 Zollinger Oct 2015 B2
9186494 Fangrow et al. Nov 2015 B2
9192753 Lopez et al. Nov 2015 B2
9198831 Rogers Dec 2015 B2
9205243 Lopez et al. Dec 2015 B2
9205248 Wu et al. Dec 2015 B2
9212772 Ho et al. Dec 2015 B2
9220882 Belley et al. Dec 2015 B2
9234616 Carrez et al. Jan 2016 B2
9238128 Yamaguchi et al. Jan 2016 B2
9238129 Fangrow et al. Jan 2016 B2
9259565 Siopes et al. Feb 2016 B2
9278205 Quach et al. Mar 2016 B2
9278206 Fangrow et al. Mar 2016 B2
9289588 Chen Mar 2016 B2
D753283 Efinger Apr 2016 S
9314604 Bonnal et al. Apr 2016 B2
9345641 Kraus et al. May 2016 B2
9352086 Guala May 2016 B2
9366371 Naftalovitz et al. Jun 2016 B2
9370466 Garfield et al. Jun 2016 B2
9370651 Zollinger et al. Jun 2016 B2
9375559 Feith et al. Jun 2016 B2
9381339 Wu et al. Jul 2016 B2
9393398 Truitt et al. Jul 2016 B2
9409007 Yeh Aug 2016 B2
9415200 Fangrow Aug 2016 B2
9421354 Carmody et al. Aug 2016 B2
9433708 Eddy Sep 2016 B2
9440060 Fangrow Sep 2016 B2
9533137 Fangrow Jan 2017 B2
D786427 Nelson May 2017 S
D793551 Nelson Aug 2017 S
9750926 Lopez et al. Sep 2017 B2
9884176 Fangrow et al. Feb 2018 B2
D826400 Nelson Aug 2018 S
10086188 Fangrow Oct 2018 B2
D838842 Shaw et al. Jan 2019 S
10195413 Lopez et al. Feb 2019 B2
D849939 Nelson May 2019 S
10369349 Nelson Aug 2019 B2
D890335 Nelson Jul 2020 S
20010049508 Fangrow, Jr. Dec 2001 A1
20020024036 Rohrbough et al. Feb 2002 A1
20020120333 Keogh et al. Aug 2002 A1
20020156430 Haarala et al. Oct 2002 A1
20040006330 Fangrow, Jr. Jan 2004 A1
20040201216 Segal et al. Oct 2004 A1
20040221904 Usher et al. Nov 2004 A1
20050010176 Dikeman et al. Jan 2005 A1
20050020981 Kurth Jan 2005 A1
20050059952 Giuliano et al. Mar 2005 A1
20050121638 Doyle Jun 2005 A1
20050124964 Niedospial et al. Jun 2005 A1
20050212292 Parrino et al. Sep 2005 A1
20050222541 Lopez et al. Oct 2005 A1
20050234405 Dikeman et al. Oct 2005 A1
20060004331 Fangrow, Jr. Jan 2006 A1
20060161115 Fangrow, Jr. Jul 2006 A1
20060200088 Lopez Sep 2006 A1
20060200089 Lopez et al. Sep 2006 A1
20060200090 Lopez et al. Sep 2006 A1
20060206061 Lopez et al. Sep 2006 A1
20060211997 Fangrow, Jr. Sep 2006 A1
20060211998 Fangrow, Jr. Sep 2006 A1
20060211999 Fangrow, Jr. Sep 2006 A1
20060212001 Fangrow, Jr. Sep 2006 A1
20060212003 Fangrow, Jr. Sep 2006 A1
20060212006 Fangrow, Jr. Sep 2006 A1
20060224127 Fangrow, Jr. Oct 2006 A1
20060264842 Fangrow, Jr. Nov 2006 A1
20060264844 Fangrow, Jr. Nov 2006 A1
20060264849 Lopez et al. Nov 2006 A1
20060264909 Fangrow, Jr. Nov 2006 A1
20060264910 Fangrow, Jr. Nov 2006 A1
20060270999 Fangrow, Jr. Nov 2006 A1
20060271016 Fangrow, Jr. Nov 2006 A1
20060276757 Fangrow, Jr. Dec 2006 A1
20060276758 Fangrow, Jr. Dec 2006 A1
20070100284 Leinsing et al. May 2007 A1
20070106205 Connell et al. May 2007 A1
20070112312 Fangrow, Jr. May 2007 A1
20070112313 Fangrow, Jr. May 2007 A1
20070224865 Fangrow, Jr. Sep 2007 A1
20070225425 Nash et al. Sep 2007 A1
20070235676 Vangsness et al. Oct 2007 A1
20070254000 Guo et al. Nov 2007 A1
20070270756 Peppel et al. Nov 2007 A1
20080039802 Vangsness et al. Feb 2008 A1
20080086095 Dikeman et al. Apr 2008 A1
20080086097 Rasmussen et al. Apr 2008 A1
20080086099 McKinnon et al. Apr 2008 A1
20080097407 Plishka Apr 2008 A1
20080169444 Guala Jul 2008 A1
20080249508 Lopez et al. Oct 2008 A1
20090005761 Guala Jan 2009 A1
20090087606 Julien Apr 2009 A1
20090198209 Usher et al. Aug 2009 A1
20090209922 Boisjoly Aug 2009 A1
20090292252 Lareau et al. Nov 2009 A1
20090292274 Guala Nov 2009 A1
20100030163 Carrez et al. Feb 2010 A1
20100030164 Kimball et al. Feb 2010 A1
20100036330 Plishka et al. Feb 2010 A1
20100059474 Brandenburger et al. Mar 2010 A1
20100059702 Mansour et al. Mar 2010 A1
20100063456 Rahimy et al. Mar 2010 A1
20100063482 Mansour Mar 2010 A1
20100108681 Jepson et al. May 2010 A1
20100152680 Memahon Jun 2010 A1
20100174242 Anderson et al. Jul 2010 A1
20100179514 Guala Jul 2010 A1
20100241088 Ranalletta et al. Sep 2010 A1
20100249723 Fang, Jr. Sep 2010 A1
20100249724 Cote, Sr. et al. Sep 2010 A1
20100249725 Cote, Sr. et al. Sep 2010 A1
20100264343 Jeory Oct 2010 A1
20100270792 Lauer Oct 2010 A1
20100283238 Deighan et al. Nov 2010 A1
20100292673 Korogi et al. Nov 2010 A1
20100292674 Jepson et al. Nov 2010 A1
20100300556 Carmody et al. Dec 2010 A1
20100324502 Guala Dec 2010 A1
20110004183 Carrez et al. Jan 2011 A1
20110024664 Bernard et al. Feb 2011 A1
20110028914 Mansour et al. Feb 2011 A1
20110028915 Siopes et al. Feb 2011 A1
20110046572 Fangrow Feb 2011 A1
20110048540 Stroup Mar 2011 A1
20110054440 Lewis Mar 2011 A1
20110060293 Guala Mar 2011 A1
20110087164 Mosler et al. Apr 2011 A1
20110106046 Hiranuma et al. May 2011 A1
20110125104 Lynn May 2011 A1
20110130717 David et al. Jun 2011 A1
20110130724 Mansour et al. Jun 2011 A1
20110130726 Crawford et al. Jun 2011 A1
20110130727 Crawford et al. Jun 2011 A1
20110130728 McKinnon Jun 2011 A1
20110152832 Foshee et al. Jun 2011 A1
20110166532 Brandenburger et al. Jul 2011 A1
20110178493 Okiyama Jul 2011 A1
20110257590 Winsor et al. Oct 2011 A1
20110264037 Foshee et al. Oct 2011 A1
20110266477 Stroup Nov 2011 A1
20110275988 Davis et al. Nov 2011 A1
20110276010 Davis et al. Nov 2011 A1
20110276031 Hoang et al. Nov 2011 A1
20110295235 Fangrow Dec 2011 A1
20110306940 Miyasaka Dec 2011 A1
20110319821 Kitani et al. Dec 2011 A1
20110319859 Zeytoonian et al. Dec 2011 A1
20120013121 Weckstrom Jan 2012 A1
20120022469 Alpert Jan 2012 A1
20120042971 Py Feb 2012 A1
20120046636 Kriheli Feb 2012 A1
20120053529 Imai Mar 2012 A1
20120059314 Eichhorst Mar 2012 A1
20120059334 Pan Mar 2012 A1
20120059346 Sheppard et al. Mar 2012 A1
20120065626 Naftalovitz et al. Mar 2012 A1
20120095407 Chebator et al. Apr 2012 A1
20120109077 Ryan May 2012 A1
20120130305 Bonnal et al. May 2012 A1
20120130352 Naftalovitz et al. May 2012 A1
20120150129 Jin et al. Jun 2012 A1
20120153201 Larose et al. Jun 2012 A1
20120157928 Mermet Jun 2012 A1
20120157933 Newton et al. Jun 2012 A1
20120179108 Delabie Jul 2012 A1
20120192968 Bonnal et al. Aug 2012 A1
20120209238 Rosenquist et al. Aug 2012 A1
20120215182 Mansour et al. Aug 2012 A1
20120220955 Maseda et al. Aug 2012 A1
20120220977 Yow Aug 2012 A1
20120220984 Christensen et al. Aug 2012 A1
20120245564 Tekeste et al. Sep 2012 A1
20120259292 Koehler Oct 2012 A1
20120316514 Mansour Dec 2012 A1
20120316536 Carrez et al. Dec 2012 A1
20120323063 Costanzo Dec 2012 A1
20120330277 Winsor et al. Dec 2012 A1
20130012870 Dikeman et al. Jan 2013 A1
20130030386 Panian et al. Jan 2013 A1
20130035668 Kitani et al. Feb 2013 A1
20130046315 Woehr et al. Feb 2013 A1
20130053815 Mucientes et al. Feb 2013 A1
20130060205 Mansour et al. Mar 2013 A1
20130066293 Garfield et al. Mar 2013 A1
20130079730 Mosler et al. Mar 2013 A1
20130138075 Lambert May 2013 A1
20130253478 Fangrow, Jr. Sep 2013 A1
20130289534 Fangrow, Jr. Oct 2013 A1
20130331800 Newton et al. Dec 2013 A1
20140031765 Siopes et al. Jan 2014 A1
20140104608 Ozeki et al. Apr 2014 A1
20140135709 Zollinger May 2014 A1
20140142519 Truitt et al. May 2014 A1
20140155836 Truitt et al. Jun 2014 A1
20140174578 Bonnal et al. Jun 2014 A1
20140180219 Ho et al. Jun 2014 A1
20140180258 Ho et al. Jun 2014 A1
20140209197 Carrez et al. Jul 2014 A1
20140257198 Truitt et al. Sep 2014 A1
20140261860 Heath et al. Sep 2014 A1
20140276455 Yeh et al. Sep 2014 A1
20140276456 Eddy Sep 2014 A1
20140276458 Mansour et al. Sep 2014 A1
20140276459 Yeh et al. Sep 2014 A1
20140276463 Mansour et al. Sep 2014 A1
20140276466 Yeh et al. Sep 2014 A1
20140296794 Li Oct 2014 A1
20140303602 Mansour et al. Oct 2014 A1
20140316350 Yamaguchi et al. Oct 2014 A1
20140358033 Lynn Dec 2014 A1
20140371686 Sano et al. Dec 2014 A1
20150008664 Tachizaki Jan 2015 A1
20150040987 Reichert et al. Feb 2015 A1
20150040988 Reichert et al. Feb 2015 A1
20150045746 Macy, Jr. et al. Feb 2015 A1
20150045772 Reichert et al. Feb 2015 A1
20150126942 Lopez et al. May 2015 A1
20150148756 Lynn May 2015 A1
20150151100 Mansour Jun 2015 A1
20150157799 Chen et al. Jun 2015 A1
20150157800 Chen et al. Jun 2015 A1
20150157848 Wu et al. Jun 2015 A1
20150176715 Huang et al. Jun 2015 A1
20150190627 Ueda et al. Jul 2015 A1
20150196749 Ziv et al. Jul 2015 A1
20150196750 Ueda et al. Jul 2015 A1
20150202424 Harton Jul 2015 A1
20150258325 Panian et al. Sep 2015 A1
20150265827 Keyser et al. Sep 2015 A1
20150265829 Truitt et al. Sep 2015 A1
20150297817 Guala Oct 2015 A1
20150297880 Ogawa et al. Oct 2015 A1
20150313523 Chelak et al. Nov 2015 A1
20150320992 Bonnet et al. Nov 2015 A1
20150374910 Mansour Dec 2015 A1
20160000364 Mendels et al. Jan 2016 A1
20160001057 Lopez et al. Jan 2016 A1
20160015958 Ueda et al. Jan 2016 A1
20160015960 Bonnal Jan 2016 A1
20160015961 Mansour et al. Jan 2016 A1
20160022977 Ueda et al. Jan 2016 A1
20160022978 Ueda Jan 2016 A1
20160030730 Mosier et al. Feb 2016 A1
20160038730 Zollinger Feb 2016 A1
20160089492 Burnard et al. Mar 2016 A1
20160089529 Bolz et al. Mar 2016 A1
20160106970 Fangrow Apr 2016 A1
20160114147 Siopes et al. Apr 2016 A1
20160129235 Ryan May 2016 A1
20160136051 Lavi May 2016 A1
20160144110 Ueda May 2016 A1
20160158524 Quach et al. Jun 2016 A1
20160199575 Belley et al. Jul 2016 A1
20160235961 Maffei Aug 2016 A1
20160263369 Naftalovitz et al. Sep 2016 A1
20160279404 Nelson Sep 2016 A1
20160317798 Lopez et al. Nov 2016 A1
20170128710 Fangrow May 2017 A1
20180289942 Fangrow Jan 2018 A1
20180099137 Fangrow Apr 2018 A1
20190001114 Fangrow Jan 2019 A1
20190113166 Zoellner et al. Apr 2019 A1
Foreign Referenced Citations (46)
Number Date Country
1 105 959 Jul 1981 CA
2 149 725 Nov 1995 CA
2 175 021 Nov 1996 CA
636526 Jun 1983 CH
670955 Jul 1989 CH
855 319 Sep 1952 DE
84 25 197.2 Sep 1985 DE
37 40 269 Jun 1989 DE
0 263 789 Apr 1988 EP
0 309 771 Apr 1989 EP
0 399 119 Nov 1990 EP
0 446 463 Sep 1991 EP
0 805 930 Jun 2002 EP
1 466 644 Oct 2004 EP
1 547 646 Jun 2005 EP
1 563 867 Aug 2005 EP
1 854 502 Nov 2007 EP
1 857 137 Nov 2007 EP
1 669 101 Jul 2008 EP
2 004 274 Dec 2008 EP
2 707 505 Jan 1995 FR
2 000 685 Jan 1979 GB
2 001 146 Jan 1979 GB
2034 185 Jun 1980 GB
2006-43354 Feb 2006 JP
2009-299871 Dec 2009 JP
333508 Aug 2005 NZ
WO 199220736 Nov 1992 WO
WO 199422523 Oct 1994 WO
WO 199623158 Jan 1996 WO
WO 199959672 Nov 1999 WO
WO 199961093 Dec 1999 WO
WO 200020070 Apr 2000 WO
WO 2003018104 Mar 2003 WO
WO 2003086529 Oct 2003 WO
WO 2005115521 Aug 2005 WO
WO 2006013433 Feb 2006 WO
WO 2006062912 Jun 2006 WO
WO 2007112278 Oct 2007 WO
WO 2008048777 Apr 2008 WO
WO 2008062741 May 2008 WO
WO 2009052433 Apr 2009 WO
WO 2009111596 Sep 2009 WO
WO 2010004471 Jan 2010 WO
WO 2010135080 Nov 2010 WO
WO 2011064738 Jun 2011 WO
Non-Patent Literature Citations (22)
Entry
Photographs of LifeShield CLAVE®& TKO-4S product, consisting of a needleless valve essentially as illustrated in Lopez (U.S. Pat. No. 5,685,866) and a flow control valve essentially as illustrated in Dikeman (U.S. Pat. No. 7,601,141), sold in the U.S. at least as early as May 2008.
U.S. Appl. No. 29/510,851, filed Dec. 3, 2014, Nelson.
U.S. Appl. No. 29/510,852, filed Dec. 3, 2014, Nelson.
U.S. Appl. No. 29/603,008, filed May 5, 2017, Nelson.
U.S. Appl. No. 14/961,163, filed Dec. 7, 2015, Lopez et al.
U.S. Appl. No. 29/611,987, filed Jul. 27, 2017, Nelson.
“Faulding Inc. receives FDA permission to market patented Safe-Connect Valve”, dated Dec. 2, 1996.
BD Medical: Needleless IV Access Devices, one page, 2007.
Capless BackcheckValve, dated Sep. 3, 1993.
CardinalHealth, SmartSite Brochure: “SmartSite® Disposables,” 2004, in 12 pages.
Carefusion, Medegen Introduces MaxPlus® Clear, First and Only Clear Positive Displacement Connector for Use in Infusion Therapy, MaxGuard News, one page article, dated Mar. 10, 2008—Ontario, CA.
Caresite™ Luer Access Device, dated 2010.
Clearlink, needleless IV access system, Baxter 2007 brochure in 2 pages.
F.D.A. 510(k) Summary of Safety and Effectiveness, dated Nov. 17, 1997.
LifeShield TKO Anti-Reflux Device Brochure, appears to contain a date of Feb. 2008.
MEDI-4955 Liquid Silicone Rubber from NuSil Silicone Technology, dated Dec. 17, 2010.
MicroClave Connector Brochure. The MicroClave was available before Mar. 25, 2008.
MicroClave Neutral Displacement Connector A Needlefree Closed System Device. Brochure Sep. 24, 2008.
MicroClave Product Page Video Shots. Sep. 24, 2008.
Nexus Medical Nexus TKO, appears to contain a date of Mar. 2006.
PASV Valve Connector Brochure, which appears to be at least as early as Feb. 20, 2001.
Saechtling Tworzywa Sztuczne, WN-T Warszawa, 1999, V edition, pp. 224-225.
Related Publications (1)
Number Date Country
20200046961 A1 Feb 2020 US
Provisional Applications (1)
Number Date Country
61914892 Dec 2013 US
Continuations (2)
Number Date Country
Parent 15179760 Jun 2016 US
Child 16449124 US
Parent PCT/US2014/068455 Dec 2014 US
Child 15179760 US